89bio Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018
Net Income	-165.03	-142.19	-102.03	-90.12	-49.5	-57.42	Upgrade
Depreciation & Amortization	0.4	0.27	0.24	0.08	0.06	0.02	Upgrade
Share-Based Compensation	17.55	16.11	10.36	8.68	3.81	0.39	Upgrade
Other Operating Activities	8.26	-3.38	10.34	4.58	-0.61	31.55	Upgrade
Operating Cash Flow	-138.82	-129.19	-81.09	-76.78	-46.24	-25.46	Upgrade
Capital Expenditures	-0	-0	-0.01	-0.06	-0.13	-0.14	Upgrade
Change in Investments	-207.02	-123.02	-33.94	7.22	-106.71	0	Upgrade
Investing Cash Flow	-207.02	-123.02	-33.94	7.16	-106.83	-0.14	Upgrade
Share Issuance / Repurchase	216.01	512.42	118.13	3.92	157.81	87.7	Upgrade
Debt Issued / Paid	0	2.96	0	19.95	-0.16	0	Upgrade
Other Financing Activities	-3.52	-2.28	-0.3	-	0.27	20	Upgrade
Financing Cash Flow	212.49	513.11	117.83	23.87	157.92	107.7	Upgrade
Net Cash Flow	-133.36	260.91	2.8	-45.75	4.85	82.1	Upgrade
Free Cash Flow	-138.83	-129.19	-81.1	-76.84	-46.37	-25.6	Upgrade
Free Cash Flow Per Share	-1.45	-1.81	-2.33	-3.82	-2.88	-10.92	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).